Related Experiment Video
Updated: Jun 2, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Complement factor B polymorphism 32W protects against age-related macular degeneration
Anne E Hughes1, Gemma M Mullan, Declan T Bradley
1Centre for Public Health, Queen's University Belfast, UK. a.hughes@qub.ac.uk
Molecular Vision
|May 5, 2011
Summary
The complement factor B (CFB) 32W variant offers protection against age-related macular degeneration (AMD). This finding supports its functional role in the complement system, though the effect is less potent than the 32Q variant.
Area of Science:
- Genetics
- Immunology
- Ophthalmology
Background:
- Complement factor B (CFB) variants 32Q and 32W exhibit reduced in vitro complement activation compared to the common 32R variant.
- The 32Q variant is linked to a lower risk of age-related macular degeneration (AMD).
Purpose of the Study:
- To investigate whether the CFB 32W variant is also associated with a reduced risk of developing AMD.
Main Methods:
- Genotyping of 367 neovascular AMD cases and 251 controls for CFB variants.
- Logistic regression analysis incorporating CFB variants, smoking status, and genetic markers (CFH, HTRA1).
- Meta-analysis of published studies on 32W allele frequency in AMD.
Main Results:
- The CFB 32W variant demonstrated a protective association against neovascular AMD (OR=0.64, p<0.05).
- Adjusted logistic regression confirmed the protective effect (OR=0.53, p<0.05).
- Combined meta-analysis of neovascular AMD studies (n=1,795) showed a protective OR of 0.75 (p<0.05); all AMD types (n=2,600) showed OR=0.79 (p<0.01).
Conclusions:
- The CFB 32W variant is associated with protection against AMD, consistent with its functional impact on the complement system.
- The protective effect of the 32W variant is less pronounced than that of the 32Q variant.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...